Larimar Therapeutics (NASDAQ:LRMR) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06, FiscalAI reports.

Larimar Therapeutics Stock Performance

Shares of Larimar Therapeutics stock opened at $3.02 on Monday. The stock has a 50-day moving average price of $2.93 and a 200 day moving average price of $3.76. The company has a market cap of $313.73 million, a P/E ratio of -1.55 and a beta of 0.73. Larimar Therapeutics has a 1 year low of $1.91 and a 1 year high of $6.42.

Analyst Upgrades and Downgrades

LRMR has been the topic of a number of analyst reports. Wall Street Zen cut Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Finally, Leerink Partners initiated coverage on shares of Larimar Therapeutics in a report on Monday, September 14th. They issued an “outperform” rating and a $13.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $10.33.

Get Our Latest Analysis on Larimar Therapeutics

Insiders Place Their Bets

In other Larimar Therapeutics news, CEO Carole Ben-Maimon bought 18,050 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were bought at an average price of $2.77 per share, for a total transaction of $49,998.50. Following the acquisition, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. This trade represents a 4.90% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas Hamilton bought 70,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $186,900.00. Following the acquisition, the director directly owned 70,000 shares in the company, valued at $186,900. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 140,810 shares of company stock valued at $381,955. 4.00% of the stock is owned by insiders.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Read More

Earnings History for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.